Medicure Reports Financial Results for Quarter Ended September 30, 2021
WINNIPEG, MB, Nov. 22, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2021.
Quarter Ended September 30, 2021 Highlights:
- Recorded total net revenue from the sale of products of $4.9 million during the quarter ended September 30, 2021 compared to $3.5 million for the quarter ended September 30, 2020;
- Recorded total net revenue from the sale of AGGRASTAT® of $2.9 million during the quarter ended September 30, 2021 compared to $3.4 million for the quarter ended September 30, 2020;
- Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended September 30, 2021 was $282,000 compared to adjusted EBITDA of $4,000 for the quarter ended September 30, 2020;
- Net loss for the quarter ended September 30, 2021 was $946,000 compared to a net loss of $1.05 Million for the quarter ended September 30, 2020
Financial Results
Net revenues for the three months ended September 30, 2021 were $4.9 million compared to $3.5 million for the three months ended September 30, 2020. Net revenues from AGGRASTAT® for the three months ended September 30, 2021 were $2.9 million compared to $3.4 million for the three months ended September 30, 2020. ZYPITAMAG® contributed $388,000 for the three months ended September 30, 2021, compared to $105,000 for the three months ended September 30, 2020. Marley Drug™, which was acquired in December 2020, contributed $1.64 million for the three months ended September 30, 2021.
Net revenues for the nine months ended September 30, 2021 were $14.9 million compared to $9.2 million for the nine months ended September 30, 2020. Net revenues from AGGRASTAT® for the nine months ended September 30, 2021 were $8.3 million compared to $8.7 million for the nine months ended September 30, 2020. ZYPITAMAG® contributed $941,000 for the nine months ended September 30, 2021 compared to $371,000 for the nine months ended September 30, 2020. Marley Drug™ contributed $5.62 million for the nine months ended September 30, 2021. Additionally, SNP contributed $66,000, during the nine months ended September 30, 2021, compared to $53,000 for the nine months ended September 30, 2020.
The volume of AGGRASTAT® sold in Q3, 2021 was consistent with demand in Q3, 2020. The Company continues to show strong patient market share with AGGRASTAT®, and demand from hospitals, driven by the Company's sales and marketing team. There was an increase in demand for ZYPITAMAG®, which was facilitated by sale through Marley Drug™ and the Company expects growth in ZYPITAMAG® revenues going forward. Marley Drug™ sales remain consistent, and the Company expects growth in sales as marketing is expanded.
Adjusted EBITDA for Q3, 2021 was $282,000 compared to $4,000 for Q3, 2020. The increase in adjusted EBITDA for Q3, 2021 is the result of changes in research and development spending and the recovery of a liability associated with PREXXARTAN®.
Adjusted EBITDA for the nine months ended September 30, 2021 was $471,000 compared to negative $1.02 million for the nine months ended September 30, 2020. The improvement in adjusted EBITDA for the nine months ended September 30, 2020 is the result of lower selling and research and development expenses and increasing revenues with Marley Drug™ and ZYPITAMAG® sales and the recovery of a liability associated with PREXXARTAN®.
Net loss for the three months ended September 30, 2021 was $946,000 or $0.09 per share compared to net loss of $1.05 Million or $0.10 per share for the three months ended September 30, 2020.
Net loss for the nine months ended September 30, 2021 was $2.6 million or $0.26 per share compared to $2.5 million or $0.23 per share for the nine months ended September 30, 2020. The loss per share increased due to a reduced share count due to the NCIB that took place during 2020.
At September 30, 2021, the Company had unrestricted cash totaling $3.3 million up from the $2.7 million of unrestricted cash held as of December 31, 2020. Cash flows from operating activities for the nine months ended September 30, 2021 totaled $1.82 million compared to cash flows used in operating activities of $1.05 million for the nine months ended September 30, 2020.
All amounts referenced herein are in Canadian dollars unless otherwise noted.
Notes |
|
(1) |
The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EBITDA as "EBITDA adjusted for non–cash and non-recurring items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three and nine months ended September 30, 2021 and 2020 results prepared using IFRS, do not have any standardized meaning according to IFRS. It is therefore unlikely to be comparable to similar measures presented by other companies. |
(2) |
|
Conference Call Info: |
|
Topic: |
Medicure's Q3 2021 Results |
Call date: |
Tuesday, November 23, 2021 |
Time: |
7:30 AM Central Time (8:30 AM Eastern Time) |
Canada toll: |
1 (416) 764-8659 |
North American toll-free: 1 (888) 664-6392 |
|
Passcode: not required |
|
Webcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors |
|
You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website.
About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley Drug"), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug™ is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email [email protected]. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, refer to the full Prescribing Information. For additional information about ZYPITAMAG®, refer to the full Prescribing Information.
To be added to Medicure's e-mail list, please visit: http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended December 31, 2020.
AGGRASTAT® (tirofiban hydrochloride) is a registered trademark of Medicure International Inc.
Condensed Consolidated Interim Statements of Financial Position
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)
Note |
September 30, |
December 31, |
|||
Assets |
|||||
Current assets: |
|||||
Cash and cash equivalents |
$ |
3,303 |
$ |
2,716 |
|
Restricted Cash |
1,030 |
1,394 |
|||
Accounts receivable |
3) |
4,735 |
5,253 |
||
Inventories |
4) |
3,947 |
5,139 |
||
Prepaid expenses |
881 |
1,174 |
|||
Total current assets |
13,896 |
15,676 |
|||
Non–current assets: |
|||||
Property, plant and equipment |
1,698 |
1,640 |
|||
Intangible assets |
5) |
11,536 |
13,596 |
||
Goodwill |
2,988 |
2,986 |
|||
Other assets |
57 |
156 |
|||
Total non–current assets |
16,279 |
18,378 |
|||
Total assets |
$ |
30,175 |
$ |
34,054 |
|
Liabilities and Equity |
|||||
Current liabilities: |
|||||
Accounts payable and accrued liabilities |
$ |
6,177 |
$ |
6,979 |
|
Current portion of royalty obligation |
6) |
253 |
362 |
||
Current portion of acquisition payable |
5) |
637 |
637 |
||
Holdback Payable |
12) |
1,142 |
1,876 |
||
Current Portion of Contingent Consideration |
12) |
2,103 |
1,925 |
||
Income taxes payable |
164 |
164 |
|||
Current portion of lease obligation |
369 |
367 |
|||
Total current liabilities |
10,845 |
12,310 |
|||
Non–current liabilities |
|||||
Royalty obligation |
6) |
142 |
335 |
||
Acquisition payable |
5) |
1,216 |
1,132 |
||
Contingent Consideration |
12) |
56 |
51 |
||
Lease obligation |
868 |
1,080 |
|||
Total non–current liabilities |
2,282 |
2,598 |
|||
Total liabilities |
13,127 |
14,908 |
|||
Equity: |
|||||
Share capital |
7(b) |
80,915 |
80,917 |
||
Contributed surplus |
10,480 |
10,294 |
|||
Accumulated other comprehensive income |
(6,145) |
(6,497) |
|||
Deficit |
(68,202) |
(65,568) |
|||
Total Equity |
17,048 |
19,146 |
|||
Total liabilities and equity |
$ |
30,175 |
$ |
34,054 |
|
Commitments and contingencies |
9(a) & 9(d) |
||||
Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)
Note |
Three September |
Three September |
Nine September |
Nine ended September |
|||||
Revenue, net |
$ |
4,919 |
$ |
3,549 |
$ |
14,941 |
$ |
9,235 |
|
Cost of goods sold |
4 & 5) |
2,037 |
1,363 |
6,011 |
4,381 |
||||
Gross profit |
2,882 |
2,186 |
8,930 |
4,854 |
|||||
Expenses |
|||||||||
Selling |
9) |
2,601 |
923 |
7,904 |
3,963 |
||||
General and administrative |
9) |
538 |
1,264 |
1,694 |
2,834 |
||||
Research and development |
9) |
468 |
737 |
1,754 |
1,693 |
||||
3,607 |
2,924 |
11,352 |
8,490 |
||||||
Other Income: |
|||||||||
Recovery of expenses |
9(a) |
(491) |
- |
||||||
Finance (income) costs: |
|||||||||
Finance (income) expense, net |
7) |
40 |
99 |
278 |
(208) |
||||
Foreign exchange (gain) loss, net |
226 |
210 |
401 |
(936) |
|||||
266 |
309 |
188 |
(1,144) |
||||||
Net loss before income taxes |
$ |
(991) |
$ |
(1,047) |
$ |
(2,610) |
$ |
(2,492) |
|
Income tax recovery |
|||||||||
Current |
45 |
- |
(24) |
- |
|||||
Net loss |
$ |
(946) |
$ |
(1,047) |
$ |
(2,634) |
$ |
(2,492) |
|
Other comprehensive income (loss): |
|||||||||
Item that may be reclassified to profit or loss |
|||||||||
Exchange differences on translation |
(688) |
(272) |
352 |
(39) |
|||||
Other comprehensive income (loss), net of tax |
(688) |
(272) |
352 |
(39) |
|||||
Comprehensive loss |
$ |
(1,634) |
$ |
(1,319) |
$ |
(2,282) |
$ |
(2,531) |
|
Loss per share |
|||||||||
Basic |
7(d) |
$ |
(0.09) |
$ |
(0.10) |
$ |
(0.26) |
$ |
(0.23) |
Diluted |
7(d) |
$ |
(0.09) |
$ |
(0.10) |
$ |
(0.26) |
$ |
(0.23) |
Condensed Consolidated Interim Statements of Cash Flows
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)
For the nine months ended September 30 |
Note |
2021 |
2020 |
||
Cash (used in) provided by: |
|||||
Operating activities: |
|||||
Net loss for the period |
$ |
(2,634) |
$ |
(2,492) |
|
Adjustments for: |
|||||
Amortization of property, plant and equipment |
283 |
224 |
|||
Amortization of intangible assets |
5 |
2,371 |
1,838 |
||
Share–based compensation |
7(c) |
186 |
239 |
||
Write-down of inventories |
4 |
- |
311 |
||
Finance income, net |
278 |
(208) |
|||
Unrealized foreign exchange (gain) loss |
278 |
(476) |
|||
Change in the following: |
|||||
Accounts receivable |
529 |
4,022 |
|||
Inventories |
1,192 |
(185) |
|||
Other Assets |
87 |
- |
|||
Prepaid expenses |
293 |
622 |
|||
Accounts payable and accrued liabilities |
(802) |
(4,589) |
|||
Interest received, net |
55 |
26 |
|||
Income taxes paid |
(57) |
||||
Royalties paid |
6 |
(297) |
(326) |
||
Cash flows from (used in) operating activities |
1,819 |
(1,051) |
|||
Investing activities: |
|||||
Acquisition of property, plant and equipment |
(326) |
- |
|||
Acquisition of intangible assets |
5 |
(297) |
- |
||
Cash flows used in investing activities |
(623) |
- |
|||
Financing activities: |
|||||
Purchase of common shares under normal course issuer bid |
7(b) |
(2) |
(154) |
||
Repayment of lease liability |
(235) |
- |
|||
Payment of Holdback |
12 |
(372) |
- |
||
Cash flows used in financing activities |
(609) |
(154) |
|||
Foreign exchange gain on cash held in foreign currency |
- |
111 |
|||
(Decrease) increase in cash and cash equivalents |
587 |
(1,094) |
|||
Cash and cash equivalents, beginning of period |
2,716 |
12,965 |
|||
Cash and cash equivalents, end of period |
$ |
3,303 |
$ |
11,871 |
|
SOURCE Medicure Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article